R-FARM, AO

R-Pharm, AO is a diversified Russian corporation that specializes in key investment areas across industry sectors including pharmaceuticals and biotechnology, IT and digital services, fintech, and real estate development. Subsidiaries of the company include/own: R-Pharm JS (the brand name under which NPF R-Pharm carries out the development, manufacturing, and sale of medicines), R-Pharm LLC (a manufacturer of pharmaceutical products using innovative drug delivery systems), Pharmstandart (a distributor of medicines), Biosintez (developer of nutrition for premature infants and infant formula), Galileo (systems integrator for government services), RDI group (manufacturer of software, IT and telecom solutions), and Prime. Digital. Future. (a developer of electronic platforms for banks and other financial institutions). In 2023, the assets of the company include 10 plants in Russia and Kazakhstan. Net income for 2022 amounted to RUB 11.8 billion. The main owner of the group and chairman of the board of directors since 2005 is Alexei Repik. The group's revenue for 2021 was RUB 161.6 billion (US $2.214 billion), net income was RUB 6.8 billion (US$93.46 million).

Miscellaneous Nondurable Goods Merchant Wholesalers; Pharmaceutical and Medicine Manufacturing; Urban Transit Systems; Other Transit and Ground Passenger Transportation; Drugs and Druggists' Sundries Merchant Wholesalers

Nondurable Goods, Nec; Pharmaceutical Preparations; Local and Suburban Transit; Taxicabs; Drugs, Proprietaries, and Sundries

$1468.67M